Verrica Pharmaceuticals (Verrica Pharmaceuticals) Debt-to-EBITDA

: -0.52 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Verrica Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.70 Mil. Verrica Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $44.81 Mil. Verrica Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2023 was $-88.37 Mil. Verrica Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.52.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Verrica Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

VRCA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.43 Med: -0.73 Max: -0.01
Current: -0.73

During the past 8 years, the highest Debt-to-EBITDA Ratio of Verrica Pharmaceuticals was -0.01. The lowest was -1.43. And the median was -0.73.

VRCA's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.39 vs VRCA: -0.73

Verrica Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Verrica Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.01

-0.94

-1.43

-0.07

-0.73

Verrica Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.07	-0.06	-0.03	-0.48	-0.52

Competitive Comparison

For the Biotechnology subindustry, Verrica Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verrica Pharmaceuticals Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Debt-to-EBITDA falls into.

Verrica Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Verrica Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.7	+	44.81)	/	-62.197
	=	-0.73

Verrica Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.7	+	44.81)	/	-88.368
	=	-0.52

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Verrica Pharmaceuticals (NAS:VRCA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Verrica Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ted White	director, officer: President and CEO	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes	officer: General Counsel	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso	officer: Chief Commercial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Gary Goldenberg	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson	10 percent owner	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk	officer: Chief Operating Officer	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380